Wechselwirkungen · Lumeblue (previously Methylthioninium chloride Cosmo)
Lumeblue 25 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-220130 · Präparat HOS-216547
There is limited clinical information regarding the concomitant use of methylthioninium chloride with medicinal products that are metabolised by CYP isoenzymes. In vitro studies indicated that methylthioninium chloride inhibits a range of CYP isozymes in vitro, including 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5. These interactions could have a clinical relevance with narrow therapeutic index medicinal products that are metabolised by one of these enzymes (e.g., warfarin, phenytoin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, and tacrolimus).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) sirolimus (HOS-085172) ergotamine (HOS-086154) cyclosporine (HOS-084512) phenytoin (HOS-084531) warfarin (HOS-085950) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-17T16:40:00Z · SHA-256 621188d5f64a4490fe97b9da8aa94ea37b740fe8ff7b61603be8af2b1f01a404 · Passage 6718b609a37f4c29ba7701f7880fb10130d6c3204c7ba541008a1170d94fabd7 · Zeichen 1226–1818 im Abschnitt